Evidence map›Paper›PMID 31417925›Full record

ArticleWorld journal of clinical cases2019

Prevalence of anal fistula in the United Kingdom.

Suvi Rk Hokkanen, Naomi Boxall, Javaria Mona Khalid, Dimitri Bennett, Haridarshan Patel

Open access · diamondAbstract read
In one paragraph

Article in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Perianal Fistula; from Etiology to Treatment - A Review.Middle East journal of digestive diseases · 2024
    Review
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Prevalence of anal fistulas: a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Suvi Rk HokkanenReal World Evidence Solutions, IQVIA, London N19JY, United Kingdom.
Naomi BoxallReal World Evidence Solutions, IQVIA, London N19JY, United Kingdom.
Javaria Mona KhalidEvidence and Value Generation, Global Medical Affairs, Takeda Pharmaceuticals International Inc., London WC2B 4AE, United Kingdom.
Dimitri BennettDepartment of Epidemiology, Takeda Pharmaceuticals International Inc., Cambridge, MA 02139, United States; Adjunct, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
Haridarshan PatelEvidence and Value Generation, Global Medical Affairs, Takeda Pharmaceuticals International Inc., Deerfield, IL 6001, United States. hari.patel@takeda.com.
IQVIA (United Kingdom) · GBTakeda (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnal fistula is a pathological connection between the anal canal and perianal skin, which most commonly develops from an infected anal crypt. While the majority of anal fistulas are idiopathic, they are also associated with Crohn's disease (CD) and other inflammatory conditions. The prevalence of anal fistula is estimated to be 1-2 per 10000 patients, but population-based studies on anal fistula epidemiology are limited and outdated.

aimTo assess the prevalence of anal fistula and relevant comorbidities, with and without CD in the United Kingdom and Europe.

methodsA retrospective population-representative observational cohort study was performed in The Health Improvement Network (THIN), a United Kingdom primary care database. Mid-year point prevalence of anal fistula was calculated on the first of July for each year between 2014 and 2017. Estimates were calculated for anal fistula overall and by CD status and standardized to the United Kingdom and European population. Prevalence of relevant comorbidities including lymphogranuloma venereum, hidradenitis suppurativa, anal presentation of sexually transmitted diseases, diabetes mellitus, and radiation in the pelvic area was reported.

resultsThe United Kingdom-standardized overall point prevalence of anal fistula was 1.80 (95%CI: 1.65-1.94) per 10000 patients in 2017, while the Europe standardized estimate was 1.83 (95%CI: 1.68-1.98) per 10000 patients. Both these standardized point prevalence estimates ranged from 1.89 to 2.36 between 2014-2016. The United Kingdom-standardized point prevalence of anal fistula without CD was 1.35 (95%CI: 1.23-1.48) per 10000 patients, while the Europe-standardized estimate was 1.39 (95%CI: 1.26-1.52) per 10000 patients. In contrast, the standardized point prevalence estimate of anal fistula with CD was lower for both United Kingdom and Europe (0.44; 95%CI United Kingdom: 0.37-0.52, 95%CI Europe: 0.37-0.51) per 10000 patients in 2017. In 2017, 19% of anal fistula patients without CD and 13% of anal fistula patients with CD had at least one relevant comorbidity. These results show that anal fistulas are infrequent in the general population. 24.5% of prevalent anal fistulas are associated with CD, but other potentially etiological comorbidities are rare.

conclusionThis real-world evidence study estimated the United Kingdom-standardized prevalence of anal fistula was 1.80 per 10000 patients in 2017. Approximately 25% of cases may be associated with CD, while other comorbidities are rare.

Indexed as

Anal fistulaComorbiditiesCrohn’s diseaseEuropePrevalenceUnited Kingdom

Identifiers

PMID31417925
PMCPMC6692258
OpenAlexW2966706997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.